HSCS (HeartSciences) Total Equity: $2.65 Mil (As of Jan. 2026)


HSCS HeartSciences Inc HSCS
42 GF Score
Price $2.90
GF Value $2.61
Valuation Modestly Overvalued
! 7 Warning Signs
View Full Analysis

What is HeartSciences Total Equity?

HeartSciences HSCS -1.18% 42 Total Equity is $2.65 Mil as of Jan. 2026. GuruFocus rates HSCS with a GF Score™ of 42/100 and a GF Value™ of $2.61 (Modestly Overvalued). The stock has 7 warning signs investors should review.

HeartSciences's total equity for the quarter that ended in Jan. 2026 was $2.65 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

HeartSciences Total Equity Historical Data

* Premium members only.

The historical data trend for HeartSciences's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

HeartSciences Total Equity Chart

HeartSciences Annual Data
Trend Apr20 Apr21 Apr22 Apr23 Apr24 Apr25
Total Equity
Get a 7-Day Free Trial -1.91 -6.06 0.23 7.32 0.21

HeartSciences Quarterly Data
Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.79 0.21 3.14 4.18 2.65
HSCS
42GF Score
HeartSciences Inc HSCS
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

HeartSciences Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

HeartSciences's Total Equity for the fiscal year that ended in Apr. 2025 is calculated as

Total Equity=Total Assets(Q: Apr. 2025 )-Total Liabilities(Q: Apr. 2025 )
=4.223-4.018
=0.21

HeartSciences's Total Equity for the quarter that ended in Jan. 2026 is calculated as

Total Equity=Total Assets(Q: Jan. 2026 )-Total Liabilities(Q: Jan. 2026 )
=7.555-4.902
=2.65

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of $2.65 Mil mean?
HeartSciences (HSCS) has a Total Equity of $2.65 Mil as of Jan. 2026. The total amount of equity as record on a company's balance sheet. View historical data for HeartSciences and its competitors.
Is HeartSciences' Total Equity too high?
HeartSciences' current Total Equity is $2.65 Mil. Overall, HeartSciences has a GF Score™ of 42/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does HeartSciences' Total Equity compare to FEED and ITOC?
HeartSciences' Total Equity of $2.65 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Medical Devices & Instruments company?
A good Total Equity depends on the Medical Devices & Instruments industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for HeartSciences and its competitors. HeartSciences's current Total Equity is $2.65 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HeartSciences stock overvalued right now?
Based on GuruFocus' analysis, HeartSciences (HSCS) is currently considered Modestly Overvalued. The stock's GF Value™ is $2.61, compared to a current price of $2.90 — trading 11.1% above its estimated fair value. The current Total Equity is $2.65 Mil. HeartSciences' overall GF Score™ is 42/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For HeartSciences (HSCS), the current Total Equity is $2.65 Mil as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is HeartSciences (HSCS) Overvalued in 2026?

Based on GuruFocus' analysis, HeartSciences stock appears to be overvalued. The current stock price of $2.90 is trading 11.1% above its estimated GF Value™ of $2.61. GuruFocus considers HeartSciences to be Modestly Overvalued.

Key valuation signals for HSCS:

  • Total Equity: $2.65 Mil
  • GF Value™: $2.61 vs. price of $2.90 (11.1% above fair value)
  • GF Score™: 42/100 with 7 warning signs

No single metric tells the full story. See the HSCS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

HeartSciences Business Description

Address 550 Reserve Street, Suite 360, Southlake, TX, USA, 76092
HeartSciences Inc is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. Its objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. It is developing a suite of AI-ECG diagnostic solutions for use in any healthcare care setting, either via MyoVista Insights cloud-platform using one of the millions of ECG devices currently in clinical use or via MyoVista wavECG Device.
42GF Score

Get the complete analysis for HSCS

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.90
Price
$2.61
GF Value